HOOK - Hookipa Pharma Inc Stock Price, Fair Value and News

0.82USD+0.01 (+1.23%)Delayed

Market Summary

USD0.82+0.01

Delayed

1.23%

HOOK Stock Price

View Fullscreen

HOOK RSI Chart

HOOK Valuation

Market Cap

20.5M

Price/Earnings (Trailing)

-0.43

Price/Sales (Trailing)

0.38

EV/EBITDA

1.65

Price/Free Cashflow

-0.25

HOOK Price/Sales (Trailing)

HOOK Profitability

EBT Margin

-88.43%

Return on Equity

-45.44%

Return on Assets

-32.56%

Free Cashflow Yield

-403.74%

HOOK Fundamentals

HOOK Revenue

Revenue (TTM)

53.6M

Rev. Growth (Yr)

1.1K%

Rev. Growth (Qtr)

394.11%

HOOK Earnings

Earnings (TTM)

-47.5M

Earnings Growth (Yr)

173.17%

Earnings Growth (Qtr)

158.02%

Breaking Down HOOK Revenue

Last 7 days

6.5%

Last 30 days

7.9%

Last 90 days

24.2%

Trailing 12 Months

-39.3%

How does HOOK drawdown profile look like?

HOOK Financial Health

Current Ratio

4.5

HOOK Investor Care

Diluted EPS (TTM)

-0.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	53.6M	0	0	0
2023	16.0M	15.9M	20.6M	20.1M
2022	14.6M	12.0M	10.3M	14.2M
2021	21.2M	19.9M	19.7M	18.4M
2020	13.4M	16.0M	18.0M	19.6M
2019	9.9M	13.3M	13.4M	11.9M
2018	0	0	0	7.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Hookipa Pharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 21, 2023	kandera reinhard	bought	5,075	0.725	7,000	chief financial officer
Aug 16, 2023	kandera reinhard	bought	5,712	0.714	8,000	chief financial officer
Jul 11, 2023	aldag jorn	bought	4,142	0.8284	5,000	chief executive officer
Jul 07, 2023	aldag jorn	bought	4,050	0.81	5,000	chief executive officer
Jul 05, 2023	aldag jorn	bought	4,450	0.89	5,000	chief executive officer
Jul 03, 2023	aldag jorn	bought	4,455	0.8911	5,000	chief executive officer
Jun 30, 2023	kandera reinhard	bought	10,560	0.88	12,000	chief financial officer
Feb 01, 2022	necina roman	acquired	38,676	3.00	12,892	chief technology officer
Feb 01, 2022	baker christine d.	acquired	40,974	3.00	13,658	chief business officer
Feb 01, 2022	kandera reinhard	acquired	42,168	3.00	14,056	chief financial officer

Which funds bought or sold HOOK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	18,514	18,514	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-66,534	-	-%
May 15, 2024	Redmile Group, LLC	unchanged	-	-104,249	757,404	0.03%
May 15, 2024	Knoll Capital Management, LLC	unchanged	-	-540,703	3,928,380	2.44%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-28.56	-17,369	29,315	-%
May 15, 2024	BAKER BROS. ADVISORS LP	unchanged	-	-796,558	5,787,240	0.07%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	491	54,495	67,468	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	new	-	71.00	71.00	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	-8,575	62,300	-%
May 15, 2024	Royal Bank of Canada	reduced	-4.55	-28,000	150,000	-%

Are Funds Buying or Selling HOOK?

Are funds buying HOOK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HOOK

No. of Funds

Unveiling Hookipa Pharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ecor1 capital, llc	4.8%	4,595,024	SC 13G/A
Feb 14, 2024	redmile group, llc	1.1%	1,063,769	SC 13G/A
Feb 14, 2024	baker bros. advisors lp	9.99%	8,148,985	SC 13G/A
Dec 22, 2023	gilead sciences, inc.	19.4%	18,759,465	SC 13G/A
Sep 11, 2023	fmr llc	-	0	SC 13G/A
Jun 20, 2023	knoll capital management, llc	6.8%	5,517,385	SC 13G
Feb 14, 2023	deep track capital, lp	2.37%	1,240,369	SC 13G/A
Feb 14, 2023	gilead sciences, inc.	7.2%	3,759,465	SC 13G/A
Feb 14, 2023	ecor1 capital, llc	9.1%	4,973,489	SC 13G/A
Feb 14, 2023	redmile group, llc	9.9%	5,460,768	SC 13G/A

Recent SEC filings of Hookipa Pharma Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 25, 2024	8-K	Current Report
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading

Hookipa Pharma Inc News

Latest updates

Hookipa Pharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	394.1%	36,599,000	7,407,000	6,867,000	2,679,000	3,176,000	7,828,000	2,230,000	2,746,000	1,445,000	3,895,000	3,874,000	5,378,000	5,301,000	5,163,000	4,040,000	6,685,000	3,696,000	3,618,000	2,038,000	4,051,000	2,235,000
Costs and Expenses	-33.4%	25,493,000	38,302,000	29,537,000	24,151,000	25,833,000	21,416,000	23,223,000	21,173,000	21,592,000	25,942,000	25,040,000	24,667,000	24,473,000	20,357,000	20,446,000	15,911,000	16,155,000	16,843,000	15,614,000	17,680,000	12,890,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17,680,000	12,890,000
S&GA Expenses	-100.0%	-	4,374,000	4,912,000	4,445,000	4,902,000	3,824,000	4,937,000	5,026,000	4,972,000	3,523,000	4,342,000	5,095,000	4,309,000	4,669,000	4,437,000	4,347,000	4,629,000	5,664,000	4,589,000	3,751,000	2,711,000
R&D Expenses	-4.7%	20,168,000	21,162,000	24,625,000	19,706,000	20,931,000	17,592,000	18,286,000	16,147,000	16,620,000	22,419,000	20,698,000	19,572,000	20,164,000	15,688,000	16,009,000	11,564,000	11,526,000	11,179,000	11,025,000	13,929,000	10,179,000
EBITDA Margin	78.7%	-0.82	-3.84	-3.17	-4.02	-3.89	-4.24	-6.70	-5.89	-4.86	-3.80	-3.12	-2.77	-2.14	-2.00	-2.00	-2.16	-2.99	-3.27	-2.43	-1.91	-1.97
Interest Expenses	-95.9%	2,000	49,000	49,000	97,000	122,000	108,000	105,000	231,000	243,000	227,000	234,000	218,000	219,000	199,000	194,000	166,000	227,000	227,000	227,000	210,000	213,000
Income Taxes	-100.0%	-	163,500	-	-	205,000	229,000	-	1,000	-	-	1,000	-	-	-	-	-	-	-109,000	9,000	100,000	-
Earnings Before Taxes	158.3%	14,383,000	-24,654,500	-19,066,000	-18,016,000	-19,475,000	-12,082,000	-18,280,000	-16,355,000	-17,968,000	-21,234,500	-20,039,000	-17,153,000	-17,238,000	-12,474,500	-13,589,000	-7,092,000	-10,926,000	-10,353,000	-11,376,000	-11,979,000	-9,329,000
EBT Margin	78.1%	-0.88	-4.03	-3.34	-4.26	-4.14	-4.54	-7.16	-6.32	-5.24	-4.10	-3.39	-3.04	-2.38	-2.25	-2.33	-2.48	-3.33	-3.60	-2.58	-2.05	-2.13
Net Income	158.0%	14,400,000	-24,818,000	-19,066,000	-18,016,000	-19,680,000	-12,311,000	-18,280,000	-16,356,000	-17,968,000	-21,234,500	-20,040,000	-17,153,000	-17,238,000	-12,475,000	-13,589,000	-7,092,000	-10,926,000	-10,244,000	-11,385,000	-12,079,000	-9,329,000
Net Income Margin	78.1%	-0.89	-4.05	-3.36	-4.29	-4.17	-4.56	-7.16	-6.32	-5.24	-4.10	-3.39	-3.04	-2.38	-2.25	-2.32	-2.47	-3.33	-3.60	-2.59	-2.05	-2.13
Free Cashflow	-108.4%	-24,272,000	-11,646,000	-27,137,000	-19,778,000	-3,122,000	12,538,000	-17,466,000	-19,991,000	-95,000	-18,384,000	-20,130,000	-25,356,000	-14,727,000	-11,806,000	-10,990,000	-11,587,000	-7,327,000	-9,839,000	-9,847,000	-11,588,000	-12,456,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-9.6%	146	161	164	191	163	170	152	172	196	126	142	166	170	188	121	133	136	144	152	168	102
Current Assets	-9.8%	133	147	139	168	140	147	130	149	171	102	119	143	153	172	106	118	121	128	136	151	85.00
Cash Equivalents	-20.6%	93.00	117	108	136	110	112	101	119	142	67.00	83.00	103	128	143	82.00	93.00	105	114	124	135	71.00
Net PPE	-5.3%	7.00	8.00	20.00	18.00	18.00	18.00	17.00	17.00	17.00	16.00	15.00	13.00	6.00	6.00	6.00	6.00	5.00	5.00	5.00	5.00	5.00
Liabilities	-42.2%	41.00	71.00	69.00	79.00	80.00	68.00	38.00	40.00	48.00	36.00	34.00	40.00	30.00	32.00	29.00	29.00	27.00	26.00	26.00	32.00	30.00
Current Liabilities	-29.7%	30.00	42.00	41.00	46.00	44.00	36.00	26.00	27.00	31.00	28.00	27.00	34.00	20.00	21.00	19.00	19.00	15.00	15.00	13.00	17.00	15.00
Shareholder's Equity	16.3%	105	90.00	95.00	112	83.00	103	113	132	148	90.00	108	126	140	156	92.00	104	109	118	126	136	-
Retained Earnings	3.9%	-354	-369	-344	-325	-307	-287	-275	-257	-240	-222	-201	-181	-164	-147	-134	-121	-113	-103	-92.80	-81.39	-69.31
Additional Paid-In Capital	-0.1%	467	467	446	445	398	397	396	395	394	317	315	314	311	309	232	230	228	226	223	222	4.00
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26.00	26.00	26.00	18.00	15.00	10.00	1.00
Float	-	-	-	-	72.00	-	-	-	83.00	-	-	-	238	-	-	-	207	-	-	-	101	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-115.2%	-24,156	-11,224	-24,119	-19,333	-2,848	13,137	-16,508	-18,359	1,733	-13,243	-17,644	-20,732	-14,397	-11,301	-10,365	-10,545	-7,128	-8,793	-9,485	-11,397	-12,056
Share Based Compensation	-159.7%	-249	417	574	696	658	1,001	1,040	1,381	1,621	1,777	1,719	2,627	1,521	2,265	2,147	2,151	2,094	2,104	1,872	1,206	383
Cashflow From Investing	72.5%	-116	-422	-3,018	-445	-274	-599	-958	-1,632	-1,828	-5,141	-2,486	-4,624	-330	-505	-625	-1,042	-199	-1,046	-362	-191	-400
Cashflow From Financing	-100.6%	-135	21,249	-659	45,815	-735	-196	127	-2,953	75,293	-410	-11.00	85.00	101	75,076	-222	-150	-1,284	-883	-532	76,009	35,157

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

HOOK Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)
Revenue from collaboration and licensing	$ 36,599	$ 3,176
Revenue from Contract with Customer, Product and Service [Extensible List]	hook:CollaborationAndLicensingMember	hook:CollaborationAndLicensingMember
Operating expenses:
Research and development	$ (20,168)	$ (20,931)
General and administrative	(4,056)	(4,902)
Restructuring	(1,269)
Total operating expenses	(25,493)	(25,833)
Income (loss) from operations	11,106	(22,657)
Other income (expense):
Grant income	2,233	2,353
Interest income	1,331	1,171
Interest expense	(2)	(122)
Other income and (expenses), net	(285)	(220)
Total other income, net	3,277	3,182
Net income (loss) before tax	14,383	(19,475)
Income tax expense	0	(205)
Net income (loss)	14,383	(19,680)
Other comprehensive (loss) income:
Foreign currency translation gain (loss), net of tax	531	(17)
Comprehensive income (loss)	$ 14,914	$ (19,697)
Net income (loss) per share - basic	$ 0.11	$ (0.27)
Net income (loss) per share - diluted	$ 0.11	$ (0.27)

HOOK Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 92,751	$ 117,096
Accounts receivable	10,212	511
Receivable research incentives	20,557	18,760
Prepaid expenses and other current assets	9,190	10,749
Total current assets	132,710	147,116
Non-current assets:
Restricted cash	204	425
Property, plant and equipment, net	7,332	7,742
Operating lease right of use assets	4,965	5,473
Other non-current assets	660	581
Total non-current assets	13,161	14,221
Total assets	145,871	161,337
Current liabilities
Accounts payable	11,201	12,498
Deferred revenues	4,649	14,631
Operating lease liabilities, current	1,584	1,638
Accrued expenses and other current liabilities	10,930	12,101
Loans payable, current	1,144	1,120
Total current liabilities	29,508	41,988
Non-current liabilities
Operating lease liabilities, non-current	3,354	3,801
Deferred revenues, non-current	2,617	19,674
Other non-current liabilities	5,870	6,017
Total non-current liabilities	11,841	29,492
Total liabilities	41,349	71,480
Commitments and contingencies (Note 13)
Stockholders' equity:
Preferred Stock	0	0
Additional paid-in capital	466,792	467,041
Accumulated other comprehensive loss	(7,402)	(7,933)
Accumulated deficit	(354,878)	(369,261)
Total stockholders' equity	104,522	89,857
Total liabilities and stockholders' equity	145,871	161,337
Common stock
Stockholders' equity:
Common stock	10	10
Class A common stock
Stockholders' equity:
Common stock	$ 0	$ 0

About Hookipa Pharma Inc

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.

CEO	Mr. Joern Aldag
WEBSITE	hookipapharma.com
INDUSTRY	Biotechnology
EMPLOYEES	156

Hookipa Pharma Inc Frequently Asked Questions

What is the ticker symbol for Hookipa Pharma Inc? What does HOOK stand for in stocks?

HOOK is the stock ticker symbol of Hookipa Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Hookipa Pharma Inc (HOOK)?

As of Fri May 17 2024, market cap of Hookipa Pharma Inc is 20.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HOOK stock?

You can check HOOK's fair value in chart for subscribers.

What is the fair value of HOOK stock?

You can check HOOK's fair value in chart for subscribers. The fair value of Hookipa Pharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Hookipa Pharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HOOK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Hookipa Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether HOOK is over valued or under valued. Whether Hookipa Pharma Inc is cheap or expensive depends on the assumptions which impact Hookipa Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HOOK.

What is Hookipa Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, HOOK's PE ratio (Price to Earnings) is -0.43 and Price to Sales (PS) ratio is 0.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HOOK PE ratio will change depending on the future growth rate expectations of investors.